CTI Biotechnology (Suzhou) Co., Ltd.

CTI Biotechnology (Suzhou) Co., Ltd.(hereinafter referred as CTI BIO) is a CRO company specializing in the preclinical research for new drugs,invested by Centre Testing International Corporation (Stock Code: 300012) in 2011 in Kunshan Suzhou. Now CTI BIO is a professional drug safety evaluation center with advanced facilities, first -class technology and strong technical strength.Authorized certificates:China Food & Drug Adminstration official GLP certificate (February 2016).The laboratory accreditation certificate ofChina National Accreditation Commit -tee for conformity assessment (CNAS) (September 2017).AAALAC International full accreditation (November 2017). We are committed to providing one-stop technical service, such as safety evaluation, pharmacokinetic/toxicokinetic bioanalysis and pharmacodynamics, for customers of domestic and oversea biomedical enterprises and scientific research institutions.

CTI BIO has geographical advantages by nature: located in Kunshan New & High-Tech Development Zone, adjacent to Suzhou Industrial Park Zone, with new drug innovation base Shanghai in east, enjoying the geographical advantage in the core position of Yangtze River Delta medicine industrial cluster.CTI BIO occupies 72 mu, and the facility of Phase I project covers 13,300 square meters with laboratories in comply with international GLP standards. CTI BIO has an excellent talent team: 3 NMPA new drug reviewers and 2 GLP investigators. The core technology team is consist of more than 150 people, including 6 members with senior professional titles, and over 60% with bachelor’s degree or above, with education background in medicine, pharmacology, toxicology, animal medicine, biology, etc..

  • Pharmacokinetics Study

  • Drug Safety Evaluation

  • Pharmacodynamic Study